Public health agency The US Food and Drug Administration on Tuesday issued its emergency use authorization (EUA) for the first antibody test authorized for use with home collected dried blood spot samples, the Symbiotica COVID-19 Self-Collected Antibody Test System.
The agency added that the samples collected at home are then sent to a Symbiotica Inc laboratory for analysis.
According to the agency, the COVID-19 Self-Collected Antibody Test System is authorized for prescription use with a fingerstick dried blood sample that is self-collected by an individual age 18 years or older or collected by an adult from an individual five years of age and older.
This test is intended to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. It is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity, said the agency.
COVID-19 antibody tests can help identify people who may have had a prior infection or who may have recovered from COVID-19. However, these tests cannot detect the presence of the SARS-CoV-2 virus to diagnose COVID-19, concluded the agency.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial